GNS Healthcare, a Cambridge, MA-based precision medicine company, completed a $10M Series C financing round.
Backers included new investors Celgene Corporation, Alexandria Real Estate Equities, and Gi Global Health Fund and exiting investors Cambia Health Solutions, California’s Heritage Provider Network, and Japan’s Mitsui & Co. U.S. subsidiary.
The company will use the funds to accelerate the development of new, cloud-based big data solutions at the intersection of precision medicine and population health.
Led by Colin Hill, CEO and co-founder, GNS Healthcare provides cloud-based solutions that apply causal machine learning technology to predict which treatments will work for which patients.
They are used by health plans, bio-pharmaceutical companies, healthcare providers, foundations, academic medical centers, and employers to solve problems, including preterm birth, end-of-life care, comparative effectiveness, medication non-adherence, metabolic syndrome, diabetes, specialty care medications, drug target discovery, patient stratification in clinical trials, and more.